Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

This article was reviewed by Darragh O’Carroll, MD. Once You Start Testosterone Therapy, Can You Stop? Key Takeaways: Spoiler ...

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute myeloid leukemia (AML), according to a new study by researchers at Penn ...

Marius Pharmaceuticals, Inc. a patient-centric healthcare company committed to advancing innovative therapies for testosterone deficiency, today announced that Health Canada has approved KYZATREX® ...